DZD9008

Phase 2Small molecule

DZD9008 is one of 51 small molecule programs targeting Locally Advanced or Metastatic NSCLC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced or Metastatic NSCLCRecruiting

Non-Small Cell Lung CancerCompleted

Locally Advanced or Metastatic NSCLCPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 1

Completed

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Navelbine

PPierre Fabre Medicament

Phase 3

24 2

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

3 3

Nanocrystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 4

DZD9008

DDizal Pharmaceuticals

Phase 2

2 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT05559645

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Completed·DDizal Pharmaceuticals·Phase 1·NCT05926180·25 enrolled

DZD9008 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutations: Cohort Study

Recruiting·PPeking Union Medical College Hospital·Preclinical·NCT05559645·180 enrolled

Hepatic Impairment1 trial

DZD9008 PK Study in Hepatic Impairment Subjects

Completed·DDizal Pharmaceuticals·Phase 1·NCT06084104·17 enrolled

Lymphoma1 trial

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

Withdrawn·DDizal Pharmaceuticals·Phase 1/2·NCT04148742

Locally Advanced or Metastatic NSCLC1 trial

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Recruiting·DDizal Pharmaceuticals·Phase 2·NCT06276283·60 enrolled

Drug Interactions1 trial

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

Completed·DDizal Pharmaceuticals·Phase 1·NCT05418582·40 enrolled

1 more indication

Adult1 trial

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

Completed·DDizal Pharmaceuticals·Phase 1·NCT04909242·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for DZD9008. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DZD9008 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DZD9008. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dizal Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDizal Pharmaceuticals

DZD9008

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Hepatic Impairment1 trial

Lymphoma1 trial

Locally Advanced or Metastatic NSCLC1 trial

Drug Interactions1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News